The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.
Hypertriglyceridaemia, an atherogenic risk factor, is a well recognised complication of uraemia, and is present in the earliest stages of the disease. Bezafibrate is an effective hypolipidaemic agent, and its effect in moderate to severe uraemia is documented in this study. Significant reductions in serum triglyceride and cholesterol have been achieved after 1 month's therapy with a reduced dosage of bezafibrate. A reduction in the hyperinsulinaemia was also seen, but no change in the fractional removal rate of injected lipid emulsion (K2) was observed. An accelerated decline in some patients' renal function was observed, which was partially reversed on cessation of treatment. Reversible elevations in the serum creatinine phosphokinase were also seen, but no patient exhibited the myositis-like syndrome associated with clofibrate.
D000328:Adult; D001629:Bezafibrate / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D003402:Creatine Kinase / Q000097:blood; D004032:Diet; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology; D007328:Insulin / Q000097:blood; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood*; D014511:Uremia / Q000150:complications*
D007328:Insulin; D014280:Triglycerides; D002784:Cholesterol; D003402:Creatine Kinase; D001629:Bezafibrate